Vivos Therapeutics' mission is to rid the world of obstructive sleep apnea (OSA). Vivos is doing this by reimagining how OSA gets treated. While Vivos' competitors focus on treating OSA symptoms, ...

Vivos to offer MyoCorrect via telemedicine for all Vivos-trained clinicians to use as therapeutic protocol in tandem with the Vivos System HIGHLANDS RANCH, Colo., March 30, 2021 (GLOBE NEWSWIRE) -- ...

Investors might want to bet on Vivos Therapeutics, Inc. (VVOS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

HIGHLANDS RANCH, Colo., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing ...

DENVER--(BUSINESS WIRE)--Vivos Therapeutics, a world leader in the treatment of obstructive sleep apnea (OSA), today announced it has entered into an exclusive licensing agreement with VSB, LLC, an ...

Richland WA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (RDGL) (OTCQB: RDGL), Vivos Inc announced today that they filed a provisional patent application on the system equipment to support precision ...

Vivos Therapeutics VVOS, a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive ...

HIGHLANDS RANCH, Colo., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative ...

Vivos Therapeutics VVOS, a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”), will ...

DENVER--(BUSINESS WIRE)--Vivos Therapeutics, a world leader in the treatment of obstructive sleep apnea (OSA), announced today that it will be a featured presenter at the March 26–27 National ...